

Edgar Filing: INCYTE GENOMICS INC - Form 10-K/A

INCYTE GENOMICS INC
Form 10-K/A
May 09, 2001

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K/A
(Amendment No. 1)

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2000
OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 0-27488

INCYTE GENOMICS, INC.
(Formerly Incyte Pharmaceuticals, Inc.)
(Exact name of registrant as specified in its charter)

Delaware
(State of other jurisdiction of incorporation or organization)
3160 Porter Drive, Palo Alto, California 94304
(Address of principal executives offices)

94-313
(IRS Employer Identification Number)
(650) 85
(Registrant's telephone number)

Securities registered to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value \$.001 per share
Series A Participating Preferred Stock Purchase Rights

Indicate by check mark whether the registrant (1) has filed all reports
required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K (Section 229.405 of this chapter) is not contained herein,
and will not be contained, to the best of registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. ☐

The aggregate market value of Common Stock held by non-affiliates (based
upon the closing sale price on the Nasdaq National Market on February 28, 2001)
was approximately \$1,105,595,000.

As of February 28, 2001, there were 65,760,321 shares of Common Stock,
\$.001 per share par value, outstanding.

Edgar Filing: INCYTE GENOMICS INC - Form 10-K/A

DOCUMENTS INCORPORATED BY REFERENCE

Items 10 (as to directors and Section 16(a) Beneficial Ownership Reporting Compliance), 11 and 12 of Part III incorporate by reference information from the registrant's proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for the registrant's 2001 Annual Meeting of Stockholders to be held on June 5, 2001.

PART III

Item 13. Certain Relationships and Related Transactions

In March 2001, Incyte Genomics, Inc. (the "Company") entered into a LifeSeq Collaboration Agreement, Patent License Agreement, Collaboration and Technology Transfer Agreement and Proteome BioKnowledge Library License Agreement with Genomic Health, Inc. ("Genomic Health"). Under these agreements, Genomic Health obtained access to the Company's LifeSeq Gold database and BioKnowledge Library and received licenses to certain of the Company's intellectual property. Amounts Genomic Health will pay the Company under these agreements are similar to those paid to the Company under agreements between the Company and unrelated third party customers. The Company received rights to certain intellectual property that Genomic Health may, in the future, develop. At the same time, the Company purchased shares of Series C Preferred Stock of Genomic Health for an aggregate purchase price of \$5.0 million which, together with shares of Series A Preferred Stock purchased in November 2000 for an aggregate purchase price of \$1.0 million, results in the Company owning approximately 10.9% of the outstanding capital stock of Genomic Health. Under certain circumstances and if Genomic Health so elects, the Company has agreed to purchase in a future offering of Genomic Health's capital stock an aggregate of \$5.0 million of the shares being sold in that offering. Randal W. Scott, Chairman of the Board of the Company, is Chairman of the Board, President and Chief Executive Officer of Genomic Health and owns more than 10% of the outstanding capital stock of Genomic Health. Persons and entities associated with Four Partners, a significant stockholder of the Company, own approximately 12.7% of the outstanding capital stock of Genomic Health.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this Amendment to Report to be signed on its behalf by the undersigned, thereunto duly authorized.

INCYTE GENOMICS, INC.

Date: May 8, 2001

By: /s/ E. Lee Bendekgey

E. Lee Bendekgey
Executive Vice President and General Counsel

EXHIBIT INDEX

Edgar Filing: INCYTE GENOMICS INC - Form 10-K/A

Exhibit Number -----	Description of Document -----
3(i) (a)	Restated Certificate of Incorporation, as amended.
3(i) (b)	Certificate of Designation of Series A Participating Preferred Stock, (incorporated Company's Annual Report on 10-K for the year ended December 31, 1998).
3(ii)	Bylaws of the Company, as amended (incorporated by reference to Exhibit 4.2 to the C Statement on Form S-3 (File No. 333-31307)).
4.1	Form of Common Stock Certificate (incorporated by reference to the exhibit of the sa Registration Statement on Form S-1 (File No. 33-68138)).
4.2	Rights Agreement dated as of September 25, 1998 between the Company and Chase Mellon L.L.C., which includes as Exhibit B, the rights certificate (incorporated by referen Company's Registration Statement on Form 8-A filed September 30, 1998).
4.3	Indenture dated as of February 4, 2000 between the Company and State Street Bank and California, N.A., as trustee (incorporated by reference to the exhibit of the same n Annual Report on Form 10-K for the year ended December 31, 1999).
10.1#	1991 Stock Plan of Incyte Pharmaceuticals, Inc., as amended and restated (the "Plan" to Exhibit 10.18 to the Company's Registration Statement on Form S-8 (File No. 333-8
10.2#	Form of Incentive Stock Option Agreement under the Plan (incorporated by reference t number to the Company's Registration Statement on Form S-1 (File No. 33-68138)).
10.3#	Form of Nonstatutory Stock Option Agreement under the Plan (incorporated by referenc number to the Company's Registration Statement on Form S-1 (File No. 33-68138)).
10.4#	Amended and Restated 1993 Directors' Stock Option Plan of Incyte Pharmaceuticals, In reference to the exhibit of the same number to the Company's Annual Report on Form 1 December 31, 1997).
10.5#	Form of Indemnity Agreement between the Company and its directors and officers (inco Exhibit 10.5 to the Company's Registration Statement on Form S-1 (File No. 33-68138)
10.6	Lease Agreement dated December 8, 1994 between the Company and Matadero Creek (inco Exhibit 10.16 to the Company's Annual Report on Form 10-K for the year ended Decembe
10.9	Stock Purchase Agreement dated as of June 22, 1994 between the Company and Pfizer In to Exhibit B to the Company's Current Report on Form 8-K dated June 23, 1994).
10.10	Registration Rights Agreement dated as of June 22, 1994 between the Company and Pfiz reference to Exhibit C to the Company's Current Report on Form 8-K dated June 23, 19
10.11	Stock Purchase Agreement dated as of November 30, 1994 between the Company and The U by reference to Exhibit B to the Company's Current Report on Form 8-K dated November Form 8-K/A filed with the Commission on March 27, 1995).
10.12	Registration Rights Agreement dated as of November 30, 1994 between the Company and (incorporated by reference to Exhibit C to the Company's Current Report on Form 8-K

Exhibit Number -----	Description of Document -----
----------------------------	----------------------------------

Edgar Filing: INCYTE GENOMICS INC - Form 10-K/A

- 10.13 Registration Rights Agreement dated as of February 4, 2000 among the Company and Deu and Warburg Dillon Read LLC (incorporated by reference to the exhibit of the same nu Report on Form 10-K for the year ended December 31, 1999).
- 10.14 Lease Agreement dated June 19, 1997 between the Company and The Board of Trustees of University (incorporated by reference to the exhibit of the same number to the Compa 10-K for the year ended December 31, 1999).
- 10.15# 1997 Employee Stock Purchase Plan of Incyte Pharmaceuticals, Inc. (incorporated by r the Company's Registration Statement on Form S-8 (File No. 333-31409)).
- 10.16# 1998 Amendment to the 1997 Employee Stock Purchase Plan of Incyte Pharmaceuticals, I reference to Exhibit 99 to the Company's Quarterly Report on Form 10-Q for the quart
- 10.17+ Master Strategic Relationship Agreement dated as of September 2, 1997 between SmithK Incyte Pharmaceuticals, Inc. and diaDexus, LLC (incorporated by reference to Exhibit Quarterly Report on Form 10-Q/A for the quarter ended September 30, 1997).
- 10.18# 1996 Synteni, Inc. Equity Incentive Stock Plan (incorporated by reference to Exhibit Registration Statement on Form S-8 (File No. 333-46639)).
- 10.19# The Hexagen Limited Unapproved Company Share Option Plan 1996, as amended (incorpora 10.1 to the Company's Registration Statement on Form S-8 (File No. 333-67691)).
- 10.20 Stock Purchase Agreement dated as February 24, 2000 between the Company and the inve (incorporated by reference to the exhibit of the same number to the Company's Annual year ended December 31, 1999).
- 10.21 Registration Rights Agreement, dated as of December 28, 2000, by and among the Compa Proteome, Inc. (incorporated by reference to Exhibit 99.1 to the Company's Current R January 10, 2001).
- 10.22# 1998 Employee, Director and Consultant Stock Option Plan of Proteome, Inc., as amend reference to Exhibit 99.1 to the Company's Registration Statement on Form S-8 filed 333-54496)).
- 21.1 Subsidiaries of the Company.
- 23.1 Consent of Ernst & Young LLP, Independent Auditors.
- 23.2 Consent of PricewaterhouseCoopers LLP, Independent Accountants.
- 24.1 Power of Attorney.

 + Confidential treatment has been granted with respect to certain portions of these agreements.

Indicates management contract or compensatory plan or arrangement.

Copies of above exhibits not contained herein are available to any stockholder upon written request to: Investor Relations, Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94034.